Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145818 | 0.90 | L3MBTL1 (0.55) | L3MBTL1HTTDRD4CHRM2TDP1 | |
| SCHEMBL5128262 | 0.83 | GAA (0.43) | L3MBTL1HTTDRD4MEN1KMT2A | |
| SCHEMBL556793 | 0.80 | MEN1 (0.64) | L3MBTL1DRD4CHRM2TDP1MEN1 | |
| SCHEMBL3141653 | 0.80 | HTR1A (0.50) | L3MBTL1HTTCHRM2KDM4ESCN8A | |
| SCHEMBL2183492 | 0.79 | L3MBTL1 (0.47) | L3MBTL1HTTDRD4CHRM2TDP1 | |
| SCHEMBL12317 | 0.78 | L3MBTL1 (0.64) | L3MBTL1HTTDRD4CHRM2MEN1 | |
| Hydrochloric Acid SCHEMBL30321036 | 0.78 | L3MBTL1 (0.64) | L3MBTL1HTTDRD4CHRM2TDP1 | |
| SCHEMBL8252520 | 0.78 | L3MBTL1 (0.64) | L3MBTL1HTTDRD4CHRM2TDP1 | |
| SCHEMBL7427957 | 0.78 | HRH4 (0.47) | L3MBTL1CHRM2TDP1MEN1KMT2A | |
| SCHEMBL5131853 | 0.78 | L3MBTL1 (0.53) | L3MBTL1HTTCHRM2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6353017-B1 | INHIBITORS OF CATHESPINS USING DIPEPTIDE NITRILES AS ANTIINFLAMMATORY AGENTS AND ANTIARTHRITIC AGENTS | NOVARTIS AG (CH) | 2002-03-05 | — | — | US | claimed |
| US-20240238427-A1 | METHODS OF TREATING AN EYE DISORDER | KODIAK SCIENCES INC. | 2024-07-18 | — | — | US | disclosed |
| CN-118284413-A | Composition for localized bone formation | 奥斯菲治疗有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240209076-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240197810-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2024-06-20 | — | — | US | disclosed |
| WO-2024123791-A1 | FORMULATIONS FOR DUAL VEGF/IL-6 INHIBITORS | KODIAK SCIENCES INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20240084043-A1 | METHODS OF TREATING AN EYE DISORDER | KODIAK SCIENCES INC. | 2024-03-14 | — | — | US | disclosed |
| US-11912784-B2 | Methods of treating an eye disorder | KODIAK SCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4323399-A1 | METHODS OF TREATING AN EYE DISORDER | Kodiak Sciences Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-11903949-B2 | Fluoro beta-carboline compounds | OSSIFI THERAPEUTICS LLC (US) | 2024-02-20 | — | — | US | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004084843-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
| US-20040110806-A1 | Dipeptide derivatives | ALTMANN EVA (CH) | 2004-06-10 | — | — | US | disclosed |
| US-20040029814-A1 | Dipeptide nitriles | ALTMANN EVA (CH) | 2004-02-12 | — | — | US | disclosed |
| WO-2003106615-A2 | POST-CLEAVAGE SULFUR DEPROTECTION FOR CONVERGENT PROTEIN SYNTHESIS BY CHEMICAL LIGATION | GENEPROT, INC. (CH) | 2003-12-24 | — | — | WO | disclosed |
| US-6353017-B1 | INHIBITORS OF CATHESPINS USING DIPEPTIDE NITRILES AS ANTIINFLAMMATORY AGENTS AND ANTIARTHRITIC AGENTS | NOVARTIS AG (CH) | 2002-03-05 | — | — | US | disclosed |
| WO-2000048993-A1 | ARYLAMINOALKYLAMIDES | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | disclosed |
| EP-1028942-A2 | DIPEPTIDE NITRILES | Novartis AG (CH) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024460-A2 | DIPEPTIDE NITRILES | NOVARTIS AG (CH) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110806-A1 | Dipeptide derivatives | CTSL, CTSZ, CTSS | L3MBTL1 432/4885HTT 2997/4885DRD4 2934/4885 |
| US-11912784-B2 | Methods of treating an eye disorder | VEGFA, FLT4, FLT1 | L3MBTL1 3771/4885HTT 851/4885DRD4 2848/4885 |
| US-20240084043-A1 | METHODS OF TREATING AN EYE DISORDER | VEGFA, FLT4, FLT1 | L3MBTL1 3771/4885HTT 851/4885DRD4 2848/4885 |
| US-20240238427-A1 | METHODS OF TREATING AN EYE DISORDER | ALDH1A2, PDE6D, CRYAB | L3MBTL1 3722/4885HTT 2463/4885DRD4 911/4885 |
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | L3MBTL1 3589/4885HTT 396/4885DRD4 4490/4885 |
| US-20240209076-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | IL6, FLT4, TEK | L3MBTL1 1541/4885HTT 516/4885DRD4 4234/4885 |
| US-20040029814-A1 | Dipeptide nitriles | NOS1, CTSL, CTSS | L3MBTL1 965/4885HTT 2933/4885DRD4 3232/4885 |
| US-20240197810-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | L3MBTL1 2755/4885HTT 2809/4885DRD4 1118/4885 |
| US-11903949-B2 | Fluoro beta-carboline compounds | GLS, AFF1, SLC5A1 | L3MBTL1 2814/4885HTT 3230/4885DRD4 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.